Patents by Inventor Roberto Marzari

Roberto Marzari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-C5 alpha antibodies
    Patent number: 8962819
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Adienne S.A.
    Inventors: Francesco Tedesco, Roberto Marzari
  • Anti-C5 Alpha Antibodies
    Publication number: 20130071922
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: Adienne SRL
    Inventors: Francesco TEDESCO, Roberto Marzari
  • Methods of treating a disease with anti-C5 alpha antibodies
    Patent number: 8282929
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterized by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 9, 2012
    Assignee: Adienne SRL
    Inventors: Francesco Tedesco, Roberto Marzari
  • Anti-C5 Alpha Antibodies
    Publication number: 20120009184
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: July 18, 2011
    Publication date: January 12, 2012
    Applicant: ADDIENE SRL
    Inventors: Francesco TEDESCO, Roberto Marzari
  • Recombinant antibodies against CD55 and CD59 and uses thereof
    Patent number: 8034902
    Abstract: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: October 11, 2011
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Roberto Marzari, Daniele Sblattero, Francesco Tedesco
  • Anti-C5 alpha antibodies
    Patent number: 7999081
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: August 16, 2011
    Assignee: Adienne SRL
    Inventors: Francesco Tedesco, Roberto Marzari
  • Recombinant antibodies against cd55 and cd59 and uses thereof
    Publication number: 20090053225
    Abstract: The present invention relates to recombinant antibody molecules and functional fragments thereof, useful for neutralizing the complement regulatory proteins CD55 and CD59, compositions comprising the recombinant molecules and methods of using the recombinant molecules for controlling complement resistance in cancer. The present invention further relates to heterodimeric diabody molecules comprising variable regions specific for CD55/CD59 and CD20.
    Type: Application
    Filed: May 1, 2006
    Publication date: February 26, 2009
    Inventors: Roberto Marzari, Daniele Sblattero, Francesco Tedesco
  • Antibodies anti-c5 component of the complement system and their use
    Publication number: 20060115476
    Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
    Type: Application
    Filed: July 10, 2003
    Publication date: June 1, 2006
    Inventors: Francesco Tedesco, Roberto Marzari
  • Compositions and methods for selecting open reading frames
    Publication number: 20030235814
    Abstract: The current invention provides method and vectors for selecting open reading frames. Open reading frames present in a fragment of DNA cloned into the vectors of the invention result in creation of a fusion protein between the amino acid sequence encoded by the fusion protein and a reporter protein. The vector further comprises recombination sites so that once a recombinant that comprises an open reading frame is identified, either the reporter sequence or the open reading frame can be removed from the vector.
    Type: Application
    Filed: June 19, 2002
    Publication date: December 25, 2003
    Applicant: Los Alamos National Laboratory
    Inventors: Andrew R.M. Bradbury, Roberto Marzari